Heart Function Decline and Aging
Heart Function Decline and Aging
批准号:
10265347
负责人:
Wolfgang H Dillmann
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-01-01 至 2022-12-31
关键词:
3&apos Untranslated Regions5&apos Untranslated RegionsATP HydrolysisAgeAgingAnimalsAntibodiesBiological AssayCalciumCardiacCardiac Muscle ContractionCardiac MyocytesCessation of lifeChIP-seqChromatinCollaborationsComplexConsumptionContractsDNADNA ProbesDataDevelopmentDominant-Negative MutationElderlyEquipmentGene ExpressionGene Expression ProfileGeneral PopulationGenesGenetic TranscriptionHealthHealthcareHeartHeart MitochondriaHeart failureImpairmentIschemiaKnowledgeLeadLinkMediatingMessenger RNAMetabolicMetabolismMicroRNAsMitochondriaMitochondrial MatrixModelingMolecularMotorMusMutateNormal RangePathway interactionsPerformancePharmacologyPolymerasePopulationProductionProteinsProtonsReperfusion InjuryReperfusion TherapyResearchResearch PersonnelRespiratory physiologyRoleSodiumTestingTransgenesTranslation InitiationTransposaseUntranslated RegionsVeteransWorkloadadeno-associated viral vectorbaseblood pumpcalcium uniporterchromatin immunoprecipitationchromatin remodelingdeep sequencingexperimental studygain of functiongenome-wideheart functionimprovedimproved functioningin vivoknock-downlink proteinloss of functionmembermuscular structuremyocardial infarct sizingnew therapeutic targetnovelnovel strategiesnovel therapeutic interventionpressurerespiratoryresponserestorationtranscriptome sequencingtransgene expression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Heart failure (HF) is a significant health problem in the elderly population, including in Veterans. The basis for
the diminished function of the old heart (OH, 19-22 month) and increased propensity to develop HF is only
incompletely explored and poorly treated. Preliminary results show that in OH cardiac function is diminished,
cardiac myocytes (CM) contract poorly, and decreased Mitochondrial (Mito) respiratory function occurs. Our
preliminary results also show novel findings that in CM from OH versus young heart (YH, 2-3 month) the
Mitochondrial Calcium Uniporter (MCU) Complex (MCUC) has markedly decreased calcium (Ca2+) conductance
resulting in decreased Mito matrix freeCa2+ concentration ([Ca2+]m) which leads to decreased Mito respiratory,
cardiac metabolic, and contractile function. Specific MCUC member proteins show decreased levels in OH CM.
The level of the Essential MCU Regulator (EMRE) is decreased by 70% in OH CM. In the absence of EMRE,
MCUC Ca2+ conductance is lost. In addition MCU shows a more modest 30% decline in OH CM. The principle
hypothesis is that the performance of the OH can be markedly improved by restoring EMRE and MCU
levels in OH CM (OH+EMRE+MCU) using adeno-associated viral vector (AAV)-based expression of
transgenes (tges) encoding EMRE and MCU or pharmacological inhibition of Mito Ca2+ export. To test this
hypothesis we pursue three closely linked Aims. In Aim 1 we enhance MCUC Ca2+ conductance by restoring
EMRE and MCU in OH towards the YH range and determine its influence on Mito and cytosolic Ca2+ handling,
Mito respiratory, cardiac metabolic and contractile function, and animal survival. We also inhibit the Mito sodium-
Ca2+ exchanger (mNCLX) and Mito Ca2+ export with a pharmacological compound, returning [Ca2+]m to the YH
level and improving CM contraction. In Aim 2 we determine if maladaptive consequences occur in
OH+EMRE+MCU, especially increased CM death and increased myocardial infarct size (MI) with
ischemia/reperfusion (I/R). Preliminary results show a decrease in MI size in OH+EMRE+MCU versus (vs) OH.
Influences of dominant negative (dn) dnEMRE and dnMCU expression on Mito Ca2+ handling and CM contraction
in YH and OH are investigated. We compare rescue effects in OH+EMRE+MCU vs expression of a SERCa2 tge
in OH (OH+SERCa2). Preliminary results show similar basal and maximal ex vivo cardiac function in
OH+EMRE+MCU and OH+SERCa2. In Aim 3 we explore molecular mechanisms mediating the marked
decrease in EMRE protein levels in OH CM. Preliminary results point to an interaction of miRNA 215, which is
3.4-fold increased in OH CM, with the 5' UTR of EMRE mRNA inhibiting translation initiation. We also explore if
chromatin remodeling to a more open state occurs in OH+EMRE+MCU vs OH with increased DNA accessibility
enabling increased gene transcription, including of the SERCa2 gene. Chromatin remodeling involves chromatin
remodeling motors which require ATP hydrolysis. Studies in YH, OH, and OH+EMRE+MCU are conducted with
collaborators at San Diego VA and UCSD who have the expertise and equipment to perform the following
experiments. We use the Assay for Transposase-Accessible Chromatin with deep Sequencing (ATAC-Seq) and
Chromatin Immunoprecipitation Sequencing (Chip-Seq) with a Polymerase II antibody to probe DNA accessibility
for gene transcription. Chip-Seq pathway enrichment and RNA Sequencing (RNA-Seq) are used to determine
changes in gene expression. To establish a link to increased ATP levels we use CM from OH+EMRE+MCU and
OH with or without the protonophore FCCP which rapidly dissipates the proton gradient and inhibits ATP
formation. Limited preliminary results, which need to be confirmed and extended, from ATAC-Seq and Chip-Seq
indicate increased DNA accessibility in OH+EMRE+MCU vs OH CM. Chip-Seq pathway enrichment analysis
and RNA-Seq data indicate a shift in the gene expression profile to mRNAs encoding proteins linked to cardiac
muscle contraction and muscle structure development in OH+EMRE+MCU vs OH. The closely linked Aims will
lead to new knowledge and may result in novel therapeutic approaches.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Heart Function Decline and Aging
-
批准号:10427227
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Wolfgang H Dillmann
-
依托单位:
Heart Vascular Function and Thyroid Hormone Receptors
-
批准号:8140390
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:Wolfgang H Dillmann
-
依托单位:
Heart Vascular Function and Thyroid Hormone Receptors
-
批准号:8262605
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:Wolfgang H Dillmann
-
依托单位:
MECHANISM OF DIABETIC CARDIOMYOPATHY
-
批准号:8361919
-
项目类别:
-
资助金额:$2.47万
-
财政年份:2011
-
负责人:Wolfgang H Dillmann
-
依托单位:
Heart Vascular Function and Thyroid Hormone Receptors
-
批准号:8398969
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:Wolfgang H Dillmann
-
依托单位:
Heart Vascular Function and Thyroid Hormone Receptors
-
批准号:8696825
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:Wolfgang H Dillmann
-
依托单位:
MECHANISM OF DIABETIC CARDIOMYOPATHY
-
批准号:8169620
-
项目类别:
-
资助金额:$1.19万
-
财政年份:2010
-
负责人:Wolfgang H Dillmann
-
依托单位:
THYROID ACTION IN THE HEART
-
批准号:7957622
-
项目类别:
-
资助金额:$1.56万
-
财政年份:2009
-
负责人:Wolfgang H Dillmann
-
依托单位:
MECHANISM OF DIABETIC CARDIOMYOPATHY
-
批准号:7957630
-
项目类别:
-
资助金额:$1.56万
-
财政年份:2009
-
负责人:Wolfgang H Dillmann
-
依托单位:
MECHANISM OF DIABETIC CARDIOMYOPATHY
-
批准号:7722464
-
项目类别:
-
资助金额:$0.98万
-
财政年份:2008
-
负责人:Wolfgang H Dillmann
-
依托单位:
THYROID ACTION IN THE HEART
-
批准号:7722446
-
项目类别:
-
资助金额:$0.98万
-
财政年份:2008
-
负责人:Wolfgang H Dillmann
-
依托单位:
Heart Failure and Thyroid Hormone
-
批准号:7899936
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2007
-
负责人:Wolfgang H Dillmann
-
依托单位:
Heart Failure and Thyroid Hormone
-
批准号:7479371
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2007
-
负责人:Wolfgang H Dillmann
-
依托单位:
Heart Failure and Thyroid Hormone
-
批准号:7303435
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2007
-
负责人:Wolfgang H Dillmann
-
依托单位:
Heart Failure and Thyroid Hormone
-
批准号:7669147
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2007
-
负责人:Wolfgang H Dillmann
-
依托单位:
O-GlcN Acylation & Dynamin Proteins in CHF
-
批准号:8743236
-
项目类别:
-
资助金额:$49.49万
-
财政年份:2001
-
负责人:Wolfgang H Dillmann
-
依托单位:
O-GlcN Acylation & Dynamin Proteins in CHF
-
批准号:9313311
-
项目类别:
-
资助金额:$42.15万
-
财政年份:2001
-
负责人:Wolfgang H Dillmann
-
依托单位:
O-GlcN Acylation & Dynamin Proteins in CHF
-
批准号:9109468
-
项目类别:
-
资助金额:$42.15万
-
财政年份:2001
-
负责人:Wolfgang H Dillmann
-
依托单位:
O-GlcN Acylation & Dynamin Proteins in CHF
-
批准号:8647154
-
项目类别:
-
资助金额:$42.15万
-
财政年份:2001
-
负责人:Wolfgang H Dillmann
-
依托单位:
O-GlcN Acylation & Dynamin Proteins in CHF
-
批准号:8877602
-
项目类别:
-
资助金额:$49.71万
-
财政年份:2001
-
负责人:Wolfgang H Dillmann
-
依托单位:
海外基金